Aju IB Investment Co (027360) Fair Value & Analysis

Financials · KR · Market cap 397B KRW

A solid business, but screening 71% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (1,139 KRW). The favourable scenario is already priced in.
• Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder.
• For a financial, book-value and earnings-based methods matter more than a cash-flow DCF, which fits banks and insurers poorly.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.

How to read this chart

60‑month range 1,850 KRW – 18,720 KRW · fair‑value band 683.18 KRW – 1,139 KRW · the 3,165 KRW price screens above the 910.91 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Aju IB Investment Co (027360) currently trades at 3,165 KRW, while our model-based Fair Value estimate is 910.91 KRW, implying the stock looks roughly 71.2% overvalued today. The Quality Score stands at 57/100 (solid quality), in the Financials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Aju IB Investment Co generated revenue of 55.0B KRW at a net margin of 10.2%. Revenue declined 56.7% year over year. It earns a return on equity of 152.0%. Fundamentals as of Jul 22, 2026

Our scenario range runs from 683.18 KRW (bear case) to 1,139 KRW (bull case); at 3,165 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Financials peers we cover trades at 20% fair-value upside, at -71%, 027360 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Economic Profit (1,655 KRW) versus Dividend Discount (527.45 KRW). Highest evidence: Residual Income (76).

Key figures & financial health

Quality Score breakdown

About the company

Aju IB Investment Co., Ltd. is a venture capital and private equity arm of AJU Corporation Co., Ltd. It specializes in mezzanine, buyouts, corporate restructuring, and all stages of venture investments in small to medium sized start-up companies in South Korea.

Full company description

Aju IB Investment Co., Ltd. is a venture capital and private equity arm of AJU Corporation Co., Ltd. It specializes in mezzanine, buyouts, corporate restructuring, and all stages of venture investments in small to medium sized start-up companies in South Korea. The firm considers investments in information technology including mobile service platforms, software, semiconductor, contents, biotechnology, life science, and environment sectors. For venture capital investments, it focuses on high technology sector and for private equity investments, the firm focuses on manufacturing sector. It typically invests in South Korea but also makes investments in other countries. The firm also considers investments in companies with main business in immune system platform technology, oncology drugs, and ophthalmic drugs. It also invests in information communication technology including Internet of Things, artificial intelligence, smart car, and advanced materials. The firm considers investments in companies that have been evaluated by technology credit bureaus or in companies with ratings of T5 and above, which is provided by technology credit bureaus. For the investments by the office in Boston, Massachusetts, the firm primarily invests in therapeutics serving large unmet medical need; enabling platform technologies with maturing lead candidate; potential for partnership or alliance with Korean pharmaceutical companies; other areas of interest are medical devices & diagnostics. It prefers to invest between $0.87 million to $2.61 million for venture capital investments and $4.36 million to $17.45 million for private equity investments. The firm typically exits through IPO and mergers and acquisitions. Aju IB Investment Co., Ltd., formerly known as Kibo Technology Advancing Capital Co., was founded in 1974 and is based in Seoul, South Korea with additional offices in Boston, Massachusetts and San Francisco, California.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Aju IB Investment Co reported revenue of 31.3B KRW in FY2025 versus 132B KRW in FY2021, a compound −30.3%/yr. Reported net income was 8.3B KRW in FY2025, compounding −32.2%/yr from FY2021.

027360 screens 71% overvalued. Compare with Affiliated Managers Group →

Peer Group

Investment Banking & Investment Services · 17 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Investment Banking & Investment Services stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).

Explore undervalued stocks

More undervalued Financial Services stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.